Movement disorders associated with aripiprazole use: a case series.
作者： DEBORAH A. HALL , PINKY AGARWAL , ALIDA GRIFFITH , VICKI SEGRO , LAUREN C. SEEBERGER
DOI: 10.3109/00207450903225553
关键词:
摘要: … One week after stopping aripiprazole, orobuccolingual dyskinesias emerged accompanied by involuntary, grunting vocalizations, consistent with tardive dyskinesia. The patient …
sci-hub.se 参考文章(15)
Guy Maytal, Michael Ostacher, Theodore A. Stern, Aripiprazole-related tardive dyskinesia. Cns Spectrums. ,vol. 11, pp. 435- 439 ,(2006) , 10.1017/S1092852900014632
Oscar H. Brook, Hein P.J. van Hout, Wim A.B. Stalman, Marten de Haan, Nontricyclic antidepressants - Predictors of nonadherence Journal of Clinical Psychopharmacology. ,vol. 26, pp. 643- 647 ,(2006) , 10.1097/01.JCP.0000246217.34024.53
Joseph H. Friedman, Robert M. Berman, Christopher G. Goetz, Stewart A. Factor, William G. Ondo, Joanne Wojcieszek, William H. Carson, Ronald N. Marcus, Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease Movement Disorders. ,vol. 21, pp. 2078- 2081 ,(2006) , 10.1002/MDS.21091
John M. Kane, William H. Carson, Anutosh R. Saha, Robert D. McQuade, Gary G. Ingenito, Dan L. Zimbroff, Mirza W. Ali, Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. ,vol. 63, pp. 763- 771 ,(2002) , 10.4088/JCP.V63N0903
Nandini Chakraborty, Timothy Johnston, Aripiprazole and neuroleptic malignant syndrome. International Clinical Psychopharmacology. ,vol. 19, pp. 351- 353 ,(2004) , 10.1097/00004850-200411000-00007
C. Tamminga, A. Carlsson, Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis. Current Drug Targets - Cns & Neurological Disorders. ,vol. 1, pp. 141- 147 ,(2002) , 10.2174/1568007024606195
Seth Hammerman, Christopher Lam, Stanley N. Caroff, Neuroleptic malignant syndrome and aripiprazole Journal of the American Academy of Child and Adolescent Psychiatry. ,vol. 45, pp. 639- 641 ,(2006) , 10.1097/01.CHI.0000209786.29479.74
Hubert H. Fernandez, Martha E. Trieschmann, Joseph H. Friedman, Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clinical Neuropharmacology. ,vol. 27, pp. 4- 5 ,(2004) , 10.1097/00002826-200401000-00003
Shaun Jordan, Vuk Koprivica, Ruoyan Chen, Katsura Tottori, Tetsuro Kikuchi, C.Anthony Altar, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology. ,vol. 441, pp. 137- 140 ,(2002) , 10.1016/S0014-2999(02)01532-7
Narsimha R. Pinninti, Rajnish Mago, Adityanjee, Tardive dystonia-associated prescription of aripiprazole. Journal of Neuropsychiatry and Clinical Neurosciences. ,vol. 18, pp. 426- 427 ,(2006) , 10.1176/JNP.2006.18.3.426A